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   Cortical malformations from altered development are common causes of human epilepsy. 
The cellular mechanisms responsible for the epileptic state of cortex remain unclear and a 
significant portion of these cases do not respond to treatment. Previous electrophysiological 
recordings in the Jacobs lab in a rat polymicrogyria model indicated an increased response to 
group I metabotropic glutamate receptor agonists in the region adjacent to the malformation 
(PMZ). In addition there was a novel response in low threshold spiking (LTS) interneurons via 
mGluR5 activation. To determine whether cell specific expression of these receptors was altered 
in malformed cortex immunohistochemical stains were performed for group I mGluRs along 
with non-overlapping interneuron subtype specific markers, a neuronal marker and general 
inhibitory cell marker. There was no altered mGluR5 expression seen in the PMZ. There was an 
altered expression seen in PMZ mGluR1α labeled cells and cells in other cortical regions. 
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1.1 Thesis Overview: 
A significant proportion of intractable epilepsies are associated with developmental 
cortical malformations. The difficulty in treating this type of epilepsy is due in part to the fact 
that the cellular mechanisms that contribute to the hyperexcitable state of malformed cortex are 
not fully understood. The Jacobs lab has been determining the contribution of group I 
metabotropic glutamate receptors (mGluRI) to epileptogenic cortex using a known animal model 
for the human cortical developmental malformation, polymicrogyria.  Interneurons in microgyric 
cortex show an increased responsiveness to mGluRI agents, and therefore represent a potential 
target in the development of novel antiepileptic drugs. In evaluating the efficacy of group I 
antagonists for pharmaceutical applications, the cell specific expression of these receptors is 
relevant to potential side effects and the mechanism of action. The goal of this project was to 
determine whether there is a difference in the subtype of cells expressing mGluRI 
immunoreactivity in microgyric compared to normal rat cortex. 
1.2 Epilepsy: 
 Epilepsy is one of the most common neuronal brain disorders, affecting at least fifty 
million people worldwide (World Federation of Neurology et al., 2005). Epilepsy, defined as 
recurrent unprovoked seizures, is a debilitating condition that has great implications on the lives 
of those affected. These patients have difficulty with maintaining a driver’s license, 
relationships, social isolation, employment and educational opportunities (World Federation of 
Neurology et al., 2005). Epilepsy can be seen as an umbrella term that encompasses a vast array 
of underlying etiologies that ultimately lead to an increased propensity for synchronized neuronal 
activity within the brain (Beck and Elger, 2008).  
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1.3 Treatment/prognosis and introduction to cortical malformations (clinical): 
 The majority of patients with epilepsy respond to treatment with antiepileptic drugs 
(AEDs), however, 30-40% of patients continue to experience recurrent seizures despite 
attempted drug treatments (Kwan and Brodie, 2006). Cortical malformations denote a major 
cause of epilepsy (Guerrini and Carrozzo, 2002). Non-pharmacological treatment options for 
refractory cases include surgery, vagal nerve stimulation and ketogenic diets (World Federation 
of Neurology et al., 2005). However, these treatments are only effective in a minority of 
malformation-associated epilepsy patients. 
Surgical resection has proved to be a successful treatment option when the seizure origin 
is located, and restricted to either a focal region or one hemisphere (Blumcke et al., 2009; 
Sisodiya, 2000). However, surgical success has been limited in epilepsies stemming from 
malformations of cortical development with only around 40% of patients remaining seizure free 
two years after surgery (Sisodiya, 2000). This limited success rate can be attributed to factors 
including: limited EEG and ECoG spatial resolution in delineating the epileptogenic zone, and 
the potential for widespread abnormalities extending beyond the localized epileptogenic region 
of cortex (Sisodiya, 2000). A specific example of epilepsy resulting from a malformation of 
cortical development that likely has limited potential for surgical treatment is polymicrogyria 
(Sisodiya, 2004).    
1.4 Polymicrogyria Background  
 Polymicrogyria is one of the most common malformations of cortical development, and 
can often be identified through magnetic resonance imaging by the presence of excessive 
abnormal cortical gyrations (Barkovich, 2010; Sisodiya, 2004). Occasionally there is fusion of 
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the overlying molecular layer resulting in an absence of visible gyri on the exterior of the cortex 
(Sisodiya, 2000). There are two defined histological presentations of this malformation 
consisting of either unlayered or four layered cortex. Unlayered polymicrogyria is caused by an 
early disruption of neuronal migration and results in an external molecular layer that does not 
follow the normal pattern of convolutions, and underlying neurons that lack laminar organization 
(Guerrini and Carrozzo, 2002). Four layered polymicrogyria, as the name suggests, is identified 
by the presence of four cortical layers instead of the six layers seen in normal cortex (Guerrini 
and Filippi, 2005). This layering pattern is consistent with a brain that has suffered an insult 
between the twentieth and twenty-fourth week of gestation (Guerrini and Carrozzo, 2002). 
Causes that have been linked to polymicrogyria have been genetic mutations, congenital 
infections, localized or diffuse in utero ischemia, and abdominal trauma during pregnancy 
(Barkovich, 2010; Montenegro et al., 2002). These events ultimately lead to a death of the deep 
cortical layers, as evidenced by the presence of a layer of intracortical laminar necrosis (Guerrini 
and Filippi, 2005; Montenegro et al., 2002). This is due to the idea that an insult during this early 
stage of development will specifically affect the deep layers which will be within the cortical 
plate, as the brain is developing in an inside out manner (Rakic and Lombroso, 1998).  
 Clinical presentations of polymicrogyria can be focal, regional, hemispheric, or involve 
the entire cortical mantle (Guerrini and Carrozzo, 2002; Sisodiya, 2004). Affected individuals 
exhibit differing levels of symptoms ranging from mild cognitive impairments to severe 
encephalopathy, spastic paresis and intractable epilepsy (Araujo et al., 2006; Guerrini and 
Carrozzo, 2002). Surgery for polymicrogyria patients with intractable epilepsy has proved 
difficult, as the epileptogenic networks have been shown to extend well beyond the visible lesion 
even in cases of focal polymicrogyria (Chassoux et al., 2008). Neurons within the malformation 
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have also been shown to be functional, which has hindered surgical success/options in cases 
where the epileptic zone includes areas of eloquent cortex (Araujo et al., 2006). Alternative 
treatment options are necessary, however, given the fact that polymicrogyria remains poorly 
understood there are currently limited options for many individuals who consequently lead a 
severely debilitated life. (Columbo 2009-for the poorly understood)  
1.5 Animal Model 
The Dvorak lab developed an animal model for four-layered microgyria in rats by 
inducing a hypoxic event. This is accomplished by focal contact freezing: applying a probe, 
cooled to negative one hundred degrees Celsius, to a rat’s exposed skull at birth for one to two 
and a half seconds. Rats are born at an early stage of development, which is equivalent to the 
eighteen to twenty-fourth gestational weeks in humans (Dvorak and Feit, 1977; Humphreys et 
al., 1991). This time period occurs before the completion of neuronal migration with part of layer 
IV being the outermost cortical layer at birth. Focal contact freezing at this time causes 
thrombosis of the blood vessels and necrosis of layers IV, V and Via (Dvorak and Feit, 1977). 
The necrosis of these layers leaves a glial scar, however, this scar does not halt neuronal 
migration as capillaries and neuroblasts destined for the I-III cortical layers survive and layer 
accordingly (Dvorak and Feit, 1977). Layer VIb survives due to its reliance on the subcortical 
vascular network, whereas the area of necrosis was reliant on pial blood vessels (Dvorak and 
Feit, 1977; Humphreys et al., 1991). The resulting layering histologically resembles a human 
four-layered microgyrus: layer 1 is continuous with the molecular layer of the adjacent normal 
six layered cortex, layer 2 consists of layer II/III neurons and is contiguous with the adjacent 
layer II/III, layer 3 is mostly a glial scar, and layer 4 consists of the persistent portion of layer 
VIb (Dvorak and Feit, 1977; Humphreys et al., 1991; Jacobs et al., 1996; Rosen et al., 1996) . 
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This layering pattern is histologically similar to that seen in human cases of polymicrogyria 
(Dvorak et al., 1978). Typical six layered cortex resumes at distances of 300-500 micrometers 
from the microsulcus (Jacobs et al., 1996). This model is significant in that it presents the idea 
that the aberrant layering seen in polymicrogyria is the result of an event that occurs in a time-
specific manner during neuroblast migration. Dvorak was able to demonstrate this by replicating 
this experiment using rat pups that were four days postnatal. By the forth postnatal day neuronal 
migration is coming to an end in rat cortex (Dvorak et al., 1978). When focal contact freezing 
was attempted at this age, the  microgyric malformation did not form (Dvorak et al., 1978). 
 Neurons located in and adjacent to the microsulcus appear to be morphologically normal 
when Nissl stains are applied to sections from animals perfused at postnatal days 21 and 60 
(Humphreys et al., 1991). However neurofilament, GFAP and glutamate stains reveal 
widespread disruption of neocortical architecture (Humphreys et al., 1991). Neurofilment 
staining is devoid in the area of the microgyrus while adjacent cortex exhibits increased staining 
in comparison to control cortex (Humphreys et al., 1991). This increase can be explained by 
either an increase in the sprouting of axodendritic processes or from the preservation of 
processes that would otherwise be eliminated. This could suggest an overabundance of excitatory 
input (Humphreys et al., 1991). Staining of glutamatergic processes also suggests there is a 
diminution of glutamatergic processes in the zone of neuronal loss and in adjacent layer VIb, as 
well as distorted placement and orientation of glutamatergic processes in layer V of the zones 
immediately adjacent to the area of neuronal loss (Humphreys et al., 1991).  
 Clinical presentations of polymicrogyria are often associated with epilepsy (Barkovich, 
2010). Similar physiological abnormalities can be seen in the Dvorak model. Cortex in this 
model exhibits a focal hyperexcitable region adjacent to the microsulcus as early as postnatal day 
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12 and is seen in rats as old as postnatal day 118 (animals older than P118 were not analyzed) 
(Jacobs et al., 1996). This hyperexcitability was evoked in vitro in cortical brain slices at 
distances one to two millimeters away from the microsulcus and was seen as variable latency 
multiphasic events characterized as epileptiform (Jacobs et al., 1996). This focal region of 
hyperexcitability is referred to as the paramicrogyral zone (PMZ) and consists of normal six-
layered cortex, which typically resumes at a distance of 300-500 micrometers from the 
microsulcus (Jacobs et al., 1996). Surgical resection of the microsulcus had no effect on the 
hyperexcitable state of the paramicrogyral zone (Prince et al., 1997). 
A hypothesis for these observations is that afferents originating from cortical and 
extracortical sites lose their targets in the microgyrus and make laminar contacts in the adjacent 
cortex (Jacobs et al., 1999b). Interestingly, at the time period when the epileptogenic activity is 
first seen in the cortex there is a reduction in the number of immunoreactive cells in a specific 
interneuron subpopulation, however, there appears to be a lack of reduction in inhibition in 
electrophysiological recordings (Jacobs and Prince, 2005). This may be due to compensatory 
sprouting and reorganization of surviving interneurons or increased afferent excitatory inputs on 
interneurons (Jacobs and Prince, 2005). 
1.6 Interneurons: 
Interneurons account for 20-30% of total neocortical neurons (Markram et al., 2004). 
Despite sharing the common trait of mostly being inhibitory cells they exhibit a diverse array of 
morphological, physiological, molecular and synaptic characteristics (Markram et al., 2004). 
Efforts have been made to classify interneurons into distinct subgroups based on each of these 
characteristics, but these classifications have often differed amongst labs. A group was recently 
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formed called the Petilla interneuron nomenclature Group or PING to define universally 
accepted terms for use in describing the anatomical, physiological and molecular features of 
GABAergic interneurons of the cerebral cortex (Ascoli et al., 2008). Ideally a classification will 
account for all three features; however, this is not always feasible.  
The distinguishing feature of interneurons is that their axon does not leave the cortex.  
They usually arborize within a column or are capable of projecting laterally between columns; 
however they do not project down into the white matter or to distant brain regions (Markram et 
al., 2004). Most interneurons receive both excitatory and inhibitory synapses on their somata. 
Different types of inhibitory neurons seem to be specific in their targeting of different neuronal 
subdomains:  dendritic, versus axonal or somal (Markram et al., 2004). Inhibitory interneurons 
are capable of changing action potential discharge phasing and synchronizing neuronal activity 
(Markram et al., 2004). This allows them to play a crucial role in the maintenance of the balance 
between excitation and inhibition.  
Alterations in inhibitory circuits are capable of creating hyperexcitable cortex and are 
believed to be responsible for some of the clinical features of psychological disorders such as 
Schizophrenia, autism and intellectual disabilities (Dichter and Ayala, 1987; Marin, 2012). There 
are two functionally distinct inhibitory networks in cortex: fast spiking (FS), and low threshold 
spiking LTS) neurons (Gibson et al., 1999). These two networks are comprised of interneurons 
that exhibit characteristic electrophysiological properties. FS interneurons fire distinct repetitive 
discharges at depolarizing potentials with almost no adaptation, whereas LTS interneurons 
demonstrate burst firing from a hyperpolarized state with adaptation (Kawaguchi, 1993). 
Interneurons of the same type are strongly interconnected through electrical synapses (FS with 
FS, and LTS with LTS), allowing for the synchronization of spikes amongst coupled 
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interneurons (Beierlein et al., 2000; Gibson et al., 1999). Interneurons within each of these 
networks share certain morphological and histological characteristics that allow for further 
classification (Gibson et al., 1999; Kawaguchi and Kondo, 2002; Kawaguchi and Kubota, 1993). 
Morphological classifications of interneurons include: large basket cells, small basket 
cells, nest basket cells, chandelier cells, Martinotti cells, bipolar cells, double bouquet cells, 
bitufted cells, and neuroglia form cells (Markram et al., 2004). In rat cortex FS interneurons are 
multipolar neurons and have been identified as basket cells and chandeleir cells. (Kawaguchi 
1993 and Kawaguchi 1997) The calcium binding protein PValbumin (PV) is used histologically 
as a marker for FS cells (Kawaguchi and Kubota, 1993). Biocytin injections in PV cells reveal 
denser axonal branches near the somata and axons that extend in a horizontal direction 
(Kawaguchi and Kubota, 1993). In addition, these cells are known to provide powerful inhibition 
that creates horizontal focally regions of excitation.  LTS cells appear to encompass both 
multipolar and bitufted interneurons, but typically extend their axons vertically to layer I and 
occasionally downwards to deeper layers (Kawaguchi, 1993). Vasointestinal Protein (VIP) and 
Somatostatin (SS) are used as non-overlapping histological markers and label non-FS 
inerneurons; VIP primarily labels double bouquet cells while SS primarily labels Martinotti cells 
(Kawaguchi and Kubota, 1997).   Both of these cell types typically have processes only within 
one column, but between layers, thus they provide interlaminar, intracolumnar inhibition. 
In the freeze lesion rat model of polymicrogyria alterations have been observed in 
interneuron development as well as their intrinsic properties (George and Jacobs, 2011; Jacobs et 
al., 1996; Prince et al., 1997; Rosen et al., 1998). At immature rat ages PV neuronal and neuropil 
staining is diminished within the microgyrus and the adjacent paramicrogyral zone compared to 
control cortex, however, this is a transient reduction that reaches control levels as the rat ages in 
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all regions except for layers IV and V immediately adjacent to the microgyrus (Jacobs et al., 
1996; Prince et al., 1997; Rosen et al., 1998). Electrophysiological recordings from rats aged 
postnatal day (P)12-17 indicate a potential increase in the efficacy of LTS cells and a 
simultaneous decrease in the efficacy of FS cells within the paramicrogyral zone (George and 
Jacobs, 2011).   
Epileptiform activity can result from decreased inhibition (Dichter and Ayala, 1987). In 
an effort to determine whether this mechanism could explain the epileptiform activity seen in the 
PMG model a number of labs have performed cell counts of immunohistochemically labeled 
GABA and GABA subtype markers. Schwarz et al performed counts on GABA-labeled cells and 
found no change in malformed cortex (Schwarz et al., 2000). They also counted PV-labeled cells 
and found no difference (Schwarz et al., 2000). In contrast Rosen et al found an initial decrease 
throughout the malformed area that was a complete change in the pattern of  PV staining (Rosen 
et al., 1998). The reduction in malformed cortex was transient and recovered by P21 (Rosen et 
al., 1998). However, there remained a persistent selective decrease of around ~20% in cell counts 
within the deep layers adjacent to the microgyrus, as well as, a loss within the microgyrus itself 
(Rosen et al., 1998).  
There were two significant differences between the methods employed by Schwarz and 
Rosen. The first difference was in the age of the animals studied which was much older in the 
Schwarz study (two to four months old). Secondly, all cells from the pia to white matter were 
counted in the Schwarz study. This may have masked the specific deep layer result determined in 
the Rosen study (Intro Fig A).  
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 One change that was observed by the Schwarz group was an increase in cells that labeled 
for the marker calbindin. Calbindin is found in interneurons that label for PV and SS(Kawaguchi 
and Kubota, 1997). Since a decrease was already found in the PV interneurons, the increase in 
calbindin was suspected to be due to an increase in the number of SS interneurons. However, a 
study by Connors that specifically looked only in the deep layers adjacent to the microgyrus 
(Intro Fig A), found no difference in the number of SS-labeled neurons (Patrick et al., 2006). The 
Jacobs lab has also recently conducted stereological counts for PV, SS and VIP markers 
(unpublished Ezure and Jacobs). These counts did reveal selective increases in SS labeling in 
regions distinct from those analyzed by Patrick et al. An increase was seen in SS labeling within 
the microgyrus and in layer IV 2.2 mm lateral of the microgyrus. A simultaneous reduction was 
seen in PV labeling in these regions, which coincided with no overall change in glutamate 
decarboxylase (GAD) labeling (Intro Fig B). GAD is a marker for GABAergic cells. These 
results suggest that there is a differential effect seen in these two interneuron subtypes in PMG 
cortex. This very well may be due to a cortical compensation for the loss of PV neurons by an 
increase in the SS neurons.  
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Intro Fig A: Summary figure of previous immunohistochemical studies in the freeze lesion 
model of PMG in rat cortex. The microgyrus and its layers (1-4) can be seen in the middle of the 
figure and adjacent cortex with normal six layering (I-VI) can be seen on either side. Box 
placement indicates the location and relative size of the region analyzed in each study. Study 1 
shows findings from Rosen et al. as well as Prince and Jacobs. They looked in the deep layers in 
the region 1 mm lateral of the microgyrus in rats at P21-30 and saw a reduction in PV labeling. 
Study 2 was conducted by Schwarz et al. in 2-4 month old rats. They counted from pia to white 
matter and saw no change in GABA or PV labeling, but did see an increase in calbindin labeled 
cells. Patrick et al. conducted a study in rats at P13-15, focusing in the deep layers of the region 
adjacent to the microgyrus. They looked in a wider region spanning from 0.5 mm-1.5 mm lateral 
to the microgyrus. They looked at SS labeling and saw no change.  
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Intro Fig B: Summary figure of unpublished results from stereological counts conducted by the 
Jacobs lab. This study was conducted in rats at P14-16. Previous findings were confirmed: that 
there is a decrease seen in PV labeling in the deep layers adjacent to the malformation, as well 
as, no change in GAD labeling. The most interesting part of the stereology findings is that at two 
locations (within the microgyrus and layer IV 2.2 mm lateral to the microgyrus) there is a 
selective increase in SS labeling relative to GAD and a simultaneous decrease in PV labeling 
relative to GAD. There is no overall change in GAD labeling, however, there is a differential 
effect on these two interneuron sub types.  	  
	  
 
1.7 Group I Metabotropic Glutamate Receptors  
Metabotropic glutamate receptors are a heptahelical rector family of G protein coupled 
receptors that are currently divided into three groups based on sequence homology, transduction 
mechanisms and pharmacological properties (Pin and Bockaert, 1995; Tang et al., 2009). Group 
I consists of mGluR subunits 1 and 5, group II includes subunits 2 and 3, and group III is 
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comprised of subunits 4,6,7, and 8 (Tang et al., 2009). Group I mGluRs are primarily located 
postsynaptically while groups II and III are mostly presynaptic with the exception of mGluR6 
which is located postsynaptically in ‘ON’ bipolar cells of the retina (Tang et al., 2009). Both 
Group I receptors activate phospholipase C which causes an increase in diacylglycerol and 
inositoltriphosphate (Deng et al., 2004; Pin and Bockaert, 1995). These increases activate protein 
kinase C which initiates an increase in intracellular calcium levels (Deng et al., 2004). In 
contrast,  receptors from groups II and III are negatively coupled to adenylyl cyclase (Pin and 
Bockaert, 1995). Group I mGluRs have been shown to play a crucial role in cortical organization 
and synaptic modulation (Ballester-Rosado et al., 2010). They have also been identified as 
potential therapeutic targets for an assortment of neurological disorders including: epilepsy, 
Fragile X Syndrome, and Parkinson’s Disease (Bear et al., 2004; Benarroch, 2008).  
The organizational role that mGluR5 receptors play in somatosensory cortex was 
determined through the creation of a mouse line that specifically knocked out mGluR5 
expression in excitatory cortical neurons (Ballester-Rosado et al., 2010). The cortical maps in 
these animals developed abnormally with disrupted barrel formation and thalamacortical afferent 
(TCA) patterning (Ballester-Rosado et al., 2010). Layer IV cortical neurons fail to cluster into 
barrel walls and the TCAs are seen as diffuse patches (Ballester-Rosado et al., 2010). 
Eliminating mGluR5 from cortical glutamatergic neurons also affects the GABAergic network. 
A reduction in GABAergic inputs is seen in layer IV neurons in these mice (Ballester-Rosado et 
al., 2010). Additionally reduction of mGluR5 has been shown to correlate with a reduction in 
spine density in layer IV spiny neurons (Ballester-Rosado et al., 2010; Wijetunge et al., 2008). 
Group I mGluRs in the CA1 region of the hippocampus also play an active role in the 
organization of neuronal circuits through synaptic plasticity.  
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One example of group I’s role in synaptic plasticity is their involvement in long-term 
potentiation (LTP) and long-term depression (LTD) in the CA1 region of the hippocampus 
(Mellentin et al., 2006; Neyman and Manahan-Vaughan, 2008). When the mGluR5 antagonist 
MPEP was administered before high frequency tetani (HFT) both the induction and late phases 
of LTP were inhibited (Neyman and Manahan-Vaughan, 2008). When MPEP was administered 
after HFT late phases of LTP were still inhibited (Neyman and Manahan-Vaughan, 2008). MPEP 
administered before LFS, impaired but did not prevent the induction of LTD (Neyman and 
Manahan-Vaughan, 2008). Applying MPEP after LFS also significantly impaired the late phases 
of LTD. The application of the mGluR5 agonist CHPG converts short-term depression into LTD 
through the activation of protein synthesis (Neyman and Manahan-Vaughan, 2008). The 
mGluR1 antagonist LY367385 impaired the induction and late phases of both LTD and LTP 
when applied before LFS and HFT, and had no affect when applied after LFS or HFT (Neyman 
and Manahan-Vaughan, 2008). The activation of group I mGluRs likely triggers protein 
synthesis that is necessary for the persistence of synaptic plasticity (Neyman and Manahan-
Vaughan, 2008). Disruption of this mechanism has been implicated in fragile X syndrome. 
The Group I mGluR signaling pathway is altered in a model of fragile X syndrome and 
has been identified as a possible mechanism for the disorder (Bear et al., 2004; Huber et al., 
2002). This syndrome is caused by a mutation in the Fmr1 gene that encodes fragile x mental 
retardation protein (FMRP) (Huber et al., 2002). Group I mGluR activation has been shown to 
increase the production of FMRP near the synapses (Weiler et al., 1997). FMRP associates with 
the translation machinery and halts further mGluR activated protein synthesis through an end 
product inhibition mechanism (Bear et al., 2004; Weiler et al., 1997). This pathway is the manner 
in which LTD is achieved in the hippocampus and is selectively enhanced in Fmr1 knockout 
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mice, which lack FMRP (Huber et al., 2002). This has led to the theory that the neurological and 
psychiatric aspects of fragile X syndrome stem from exaggerated LTD, which may account for 
slowed synaptic maturation (Bear et al., 2004). Group I mGluRs have been proposed as 
therapeutic targets for the treatment of this syndrome (Bear et al., 2004). Both FMRP and group I 
mGluRs are widely expressed throughout the brain, which may mean that exaggerated group I 
mGluR driven protein synthesis accounts for other key features of fragile x syndrome (Bear et 
al., 2004). 
Fragile X syndrome is associated with an increased incidence of epilepsy (Bear et al., 
2004). The mGluR5 antagonist MPEP has been shown in other instances to have anticonvulsant 
applications (Borowicz et al., 2009). Combining MPEP with subprotective doses of conventional 
antiepileptic drugs shortened seizure duration and after seizure discharge duration for amygdala 
kindled seizures (Borowicz et al., 2009). Group I agonists have been shown to be capable of 
inducing synchronized spiking activity in the LTS interneuron networks via electric coupling 
amongst LTS cells (Beierlein et al., 2000). This synchronization induces a synchronized 
inhibition in RS and FS neurons, which can be seen over a distance of several hundred microns 
(Beierlein et al., 2000). The involvement of group I mGluRs in the ability of LTS cells to 
coordinate the firing pattern of most cortical neurons makes them a particular area of interest in 
the search for underlying mechanisms in hyper excitable cortex. Synchronous activity among 
LTS cells appears abruptly in rats between P12-15, which overlaps with the onset of active 
somatosensory exploration (Long et al., 2005). This timing  coincides with the developmental 
period that the cortex begins to exhibit a hyperexcitable state in the rat freeze lesion model for 
PMZ as well as with peak expression levels of mGluR5 (Jacobs et al., 1996; Wijetunge et al., 
2008). 
	  
	  
17	  
	  
Western blot analysis has revealed increased expression of mGluR5 protein in freeze 
lesioned cortex at P16 (Jacobs and Pomictor, unpublished observations). Pyramidal neurons in 
the PMZ also show an increase in frequencies of inhibitory postsynaptic currents (IPSCs) when 
the group I mGluR agonist DHPG is applied. LTS cells appear to be selectively altered in this 
region. AIDA, an mGluR1 selective antagonist, was applied prior to the addition of DHPG and 
an increase in IPSCs was only seen in microgyric tissue (George and Jacobs unpublished 
oberservations Intro Fig C). This represents a novel way to activate LTS cells via mGluR5 and 
could serve as the mechanism for epileptogenic activity. If this is the case mGluR5 antagonists 
would be an appropriate pharmacological focus for seizure management.  
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Intro Fig C: The effects of mGluRI agonists are greater in PMG compared to control cortex.  A) 
In normal aCSF, the addition of the mGluRI agonist DHPG increases the frequency of IPSCs 
recorded in layer V pyramidal neurons.   This increase is significantly larger in PMG compared 
to control cortex.  B) When mGluR1 receptors are blocked by addition of the selective antagonist 
AIDA to the bath, there is no change in IPSC frequency with the addition of DHPG in control 
cortex.  In PMG cortex there is still an increase in IPSC frequency that can be blocked by the 
mGluR5 selective antagonist, MPEP.  C) With only mGluR5 receptors active, there is still a 
large increase in the IPSC frequency, however not as large as when both mGluR1 and mGluR5 
receptors are active.  Thus in addition to increased expression and/or function of mGluR5 
receptors, there is also likely an increase in expression or function of mGluR1 receptors.  
Numbers in each column indicate the number of pyramidal neurons recorded. 
 
 At least three mGluR1 splice variants have been identified: α, β and c (Ferraguti et al., 
1998). Antibodies for the β variant has been shown to rarely label cells in cortex while α labels 
numerous cells (Ferraguti et al., 1998). Less is known of the c variant.  Immunoreactivity for 
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mGluR1α has been previously studied in rat cortex. This study found that all of the mGluR1α 
immunoreactive cells were also labeled with GABA, however, these cells accounted for only 
20% of the total number of GABA expressing cells (Stinehelfer et al., 2000). Labeled mGluR1α 
cells were seen in all cortical layers with the highest concentration found in layer V (Stinehelfer 
et al., 2000). Double labeling was performed with markers for PV and SS to distinguish the 
interneuron subtypes expressing the receptor. The majority of mGluR1α-labeled cells were found 
to express SS while only one neuron in the entire study co-labeled with PV (Stinehelfer et al., 
2000). Fluorescent labeling of oligodendrocyte (OL) cultures have also revealed transient group I 
mGluR (both 1 and 5) expression in OL precursors, which vanishes in mature OLs (~P10) (Deng 
et al., 2004). In situ hybridization has been used to verify that no non-neuronal cells express 
mGluR5 mRNA in adult rat cortex (Mudo et al., 2007). Cortical in situ hybridization labeling has 
also shown that mGluR1α mRNA signaling is intense in SS positive neurons and not found in 
PV expressing neurons (Kerner et al., 1997). The hybridization signal for mGluR5 mRNA, 
however, was significant in both PV and SS expressing neurons (Kerner et al., 1997).  
This may help explain the novel mGluR5 activation seen in LTS cells in microgyric 
cortex. These cells may be capable of producing these receptors, however, may only do so in 
specific circumstances (such as the reduction of PV) as a compensatory mechanism. In an effort 
to determine whether this may be occurring fluorescent immunohistochemical stains were 
performed to co-labeled group I mGluRs with interneuron subtype specific markers to determine 
which cell types express these receptors and whether they are differentially expressed in PMG 
cortex.   
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2.1 Freeze Lesion Induction 
 Aseptic surgery techniques were followed in the induction of the freeze lesion in P1 rat 
pups. The pups were anesthetized by placing them in an ice bath for four minutes prior to 
surgery. A rectangular probe (tip size = 2 x 5 mm) was filled with isobutene and placed in dry ice 
until temperatures of -50 degrees Celsius were reached. An incision was made in the scalps and 
the probe was placed directly on the skull approximately 2 mm lateral to the midline crossing the 
bregma and lambda. The probe was held there for five seconds then the skin was sutured and the 
pup was warmed under a lamp and returned to the dam.  
2.2 Transcardial Perfusion 
 Lesioned pups and their non-lesioned littermates were retrieved on P16-17 and 
anesthetized with isoflurane. Animals were then perfused transcardially with 0.9% saline 
followed by 4% paraformaldehyde with picric acid (0.4%). The brains were removed and 
postfixed in 4% paraformaldehyde with picric acid (0.4%) overnight. The next day, the solution 
was removed and replaced with phosphate buffered saline (PBS, 0.1M, pH 7.4) for long term 
storage.  
2.3 Slide Preparation 
 The right hemispheres of the non-lesioned brains were marked to insure correct 
hemisphere comparisons could be made. Then the brains were sectioned coronally in phosphate 
buffer (PB, 0.1M, pH 7.4) at a thickness of 40 micrometers using a Leica Vibratome. The 
hippocampus was used as a cortical landmark in the pairing of lesioned and control cortical 
sections. At least three different rats were used for each staining combination and up to three 
sections were used from each rat’s brain. Each section was washed three times in PBS for five 
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minute increments and then washed three times for ten minutes in tris buffered saline (TBS, 
0.05M, pH 7.4). The sections were then placed in a multiwall plate filled with 300 microliters of 
a blocking solution for two hours at room temperature. The blocking solution was 50% normal 
horse serum, 2.5% Triton X-100 in TBS. Then the sections were washed three times in TBS for 5 
minutes each. Sections were then incubated in 300 microliters of a solution containing the 
primary antibodies overnight on a shaker at four degrees Celsius. The solution was 10% normal 
horse serum, 2.5% Triton X-100 and the primary antibody concentration varied depending on the 
specific antibody (Methods Fig 1), in TBS.  
 The following day each section was washed three times for five minutes each in TBS. 
Sections were then incubated in a 300 microliter secondary antibody solution for three hours at 
room temperature covered on a shaker. The secondary antibody solution was comprised of 10% 
normal horse serum, 0.5% Triton X-100, and secondary antibodies at concentrations that varied 
depending on which specific primary antibodies they were paired with (Methods Fig 1), in TBS. 
Each section was then washed three times for five minutes each in TBS, followed by three 
additional washes for five minutes each in PB. Paired lesion and control sections were then 
mounted on slides with 0.01 M PB and Prolong Gold anti-fade reagent. 
 
 
 
 
 
	  
	  
23	  
	  
 
	  	   Antibody	  Concentrations	   	  	   	  	   	  	  
Staining	  
Combination	   Primary	  Antibody	   Concentration	   Secondary	  Antibody	   Concentration	  
1	   Tocris	  mGluR5	  (Rb)	  
polyclonal	  IgG	  (1mg/ml)	   1:250	  
Alexa	  Fluor	  594	  goat	  anti	  
rabbit	  IgG	  (H+L)	  (2mg/ml)	  
1:500	  
	  	  
Millipore	  (Ms)	  GAD67	  
monoclonal	  (1mg/ml)	  
1:250	  
Alexa	  Fluor	  405	  goat	  anti	  
mouse	  IgG	  (H+L)	  (2	  
mg/ml)	  
1:500	  
	  	   Millipore	  (Ms)	  Neuronal	  
Nuclei	  (NeuN)	  488	  
conjugated	  antibody	  
(1mg/ml)	  
1:1000	  
*none	  needed	  
	  	  
2	   Tocris	  mGluR5	  (Rb)	  
polyclonal	  IgG	  (1mg/ml)	  
1:250	   Alexa	  Fluor	  647	  goat	  anti	  
rabbit	  IgG	  (H+L)	  (2mg/ml)	  
1:500	  
	  	  
Sigma	  Parvalbumin	  Clone	  
Parv-­‐19	  (Ms)	  IgG1	  
1:1000	  
Alex	  Flour	  568	  goat	  anti	  
mouse	  IgG	  (H+L)	  
(2mg/ml)	  
1:1000	  
	  	  
Peninsula	  Laboratories	  
VIP	  (Gp)	  
1:1000	  
Vector	  Labs.	  Fluorescein	  
anti	  guinea	  pig	  IgG	  (H+L)	  
(1.5mg/ml)	  
1:1000	  
3	   Tocris	  mGluR5	  (Rb)	  
polyclonal	  IgG	  (1mg/ml)	  
1:250	   Alexa	  Fluor	  594	  goat	  anti	  
rabbit	  IgG	  (H+L)	  (2mg/ml)	  
1:500	  
	  	   BD	  Pharmingen	  mGluR1α	  
(Ms)	  monoclonal	  
(0.5mg/ml)	  
1:1000	  
Alexa	  Fluor	  488	  goat	  anti	  
mouse	  igG	  (H+L)	  
(2mg/ml)	  
1:1000	  
4	   BD	  Pharmingen	  mGluR1α	  
(Ms)	  monoclonal	  
(0.5mg/ml)	  
1:1000	  
Alexa	  Fluor	  647	  goat	  anti	  
mouse	  igG	  (H+L)	  
(2mg/ml)	  
1:1000	  
	  	   Peninsula	  Laboratories	  
Somatostatin-­‐14	  (Rb)	  
polyclonal	  
1:1000	   Alexa	  Fluor	  568	  goat	  anti	  
rabit	  igG	  (H+L)	  (2mg/ml)	  
1:1000	  
	  	  
Peninsula	  Laboratories	  
VIP	  (Gp)	  
1:1000	  
Vector	  Labs.	  Fluorescein	  
anti	  guinea	  pig	  IgG	  (H+L)	  
(1.5mg/ml)	  
1:1000	  
 
Methods Figure 1: The staining combinations (1-4) for slide preparations: including the 
antibodies used and concentrations. 
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2.4 Image Capturing and Analysis 
 To analyze the data in the most efficient way, we chose to use high power images to 
sample specific regions of cortex.  Images were taken at 63x magnification with a Leica TCS-
SP2 AOBS microscope. Settings were calibrated using one section for each individual stain. 
These settings were then universally applied to every section with that stain in control and PMG 
cortex. Images were taken in five locations: within the microgyrus (or analogous layer II/III in 
non-lesioned cortex), 1 mm lateral to the microgyrus in layer II/III and in layer V, and 2.5 mm 
lateral to the microgyrus in layers II/III and V (Methods Fig 2). At each of these locations 
sequential scan z stacks were captured. Each stack consisted of 12 scans at a 0.28492-micrometer 
step size, for a total depth examined of 3.4 micrometers. Leica confocal software was then used 
to average the intensities of these stacks to produce flattened images. Each image was then 
randomized by an outside individual and renamed. All of the cells within the 238.1 x 238.1 µm 
frame from the renamed images were then counted using the cell counter available in ImageJ 
software. Using this software it is possible to count cells on multiple images simultaneously. 
This was utilized to determine whether overlap occurred between different labels in double or 
triple labeled sections. After counts were completed the coding for the renamed files was 
revealed and the data was organized accordingly. Two tailed t tests were then performed for 
statistical analysis of potential differences between control and malformed cortex. 
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 Methods Figure 2: Picture displaying the cortical regions analyzed where high power confocal 
images were taken from a coronal section through a freeze lesion-induced microgyrus in rat 
somatosensory cortex. Red boxes represent 238.1 x 238.1 µm frames that were captured with the 
Leica TCS-SP2 AOBS microscope. All cells within the frame (total depth = 3.4 µm) were 
counted for each label and every combination of labels.   
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3.1 mGluR5, GAD67, and NeuN Labeling in Control and PMG Cortex  
Triple fluorescent labeling was performed with mGluR5, GAD67 and NeuN antibodies to 
determine whether there was a difference in the immunoreactivity for these markers in lesioned 
compared to control cortex (Fig 1). Numerical cell counts in the specified regions yielded no 
significant differences for each of the individual markers (Fig 2A-C). 
Since these markers were used on the same brain sections it was possible to determine 
generalizations of the overlapping labeled cell populations. 1) It was determined that mGluR5 
was found almost entirely in NeuN-labeled cells in both PMG and control cortex (Fig 3D). In the 
entirety of the study there was only one mGluR5-labeled cell that was not also immunoreactive 
for NeuN (Fig 3A-C). The one cell observed occurred in the microgyrus of a lesioned animal 
(Fig 3C). 2) Most of the cells that were immunoreactive for mGluR5 in both control and lesioned 
cortex were also positive for the GABAergic inhibitory cell marker, GAD67 (Fig 4). In addition, 
approximately half of the cells that were immunoreactive for GAD67 were also positive for 
mGluR5 and roughly five percent of the NeuN-labeled cells co-labeled for mGluR5 (Fig 2D, E).  
Both statements 1) and 2) are true for malformed cortex. There was, however a 
significant decrease in the percentage of mGluR5 cells that co-labeled for GAD67, selectively 
within the microgyrus (Fig 4G), but not within other regions of the PMG cortex. This may reflect 
an increase in mGluR5 expression in pyramidal and other excitatory neurons within this region, 
since overall numbers of mGluR5-labeled cells were not different between PMG and control 
cortex (Fig 2C).  
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Figure 1: Example of GAD (A) mGluR5 (B) and NeuN (C) immunohistochemical staining. 
Pictures are of layer III in the region comparable to the PMZ in control cortex.   
 
 
 
 
Figure 2: Counts of cells immunohistochemically labeled for Neun (A), GAD67 (B) or mGluR5 
(C) and co-labeling results (D,E).  There were no significant differences (t-tests, p>0.05) 
between control and PMG in the number of cells that labeled for Neun, GAD, or mGluR5. There 
was no difference in the percentage of Neun-labeled cells that were mGluR5 positive (D). There 
was no difference in the percentage of GAD67-labeled cells that were also mGluR5 positive (E).  
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Figure 3: Nearly every mGluR5-labeled cell is also positive for the neuronal marker Neun. 
Immunohistochemical staining for mGluR5 (A) and Neun (B), with the overlap shown in C. This 
example is from a PMG section, at a distance 1.0 mm lateral to the microsulcus in layer III. 
Yellow arrow shows only cell found that did not contain Neun. Gray arrowheads show examples 
of cells labeled for both mGluR5 and Neun. Scale bar = 20 µm. The percent of mGluR5 positive 
cells that stained for Neun is shown in D.  
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Figure 4: Examples of mGluR5 (A, D) and GAD (B, E) staining in control and malformed 
cortex. C and F show overlap between the two stains. These pictures are taken within the 
microgyrus and the comparable region in control cortex. Yellow arrows represent cells that co 
label for mGluR5 and GAD. White arrows are mGluR5 positive cells that do not label for GAD. 
G shows that selectively within the microgyrus of malformed cortex there is a decrease in the 
percentage of mGluR5-labeled cells that are also GAD positive. Scale bar = 20 µm. *= t-test, 
p<0.05. 
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3.2 mGluR5, Parv and VIP labeling in Control and PMG Cortex     
Triple fluorescent labeling was performed with mGluR5 and the two interneuron 
subpopulation markers: PV and VIP (Fig. 5). Numerical cell counts were made for each of these 
labels in the specified regions and cortical layers (Fig. 6A, 8A). There were statistically 
significant differences between the lesioned and control brain sections in these cell populations. 
There was a significant decrease in PV-labeled cells found in layer V in the region 2.5 mm 
lateral to the lesion (Fig 6A). This was similar to previous findings; however occurred in a region 
more lateral (Schwarz et al., 2000). There was also a significant decrease in VIP immunoreactive 
cells found within the microgyrus of malformed brains (Fig. 8A).  
The majority of mGluR5-immunoreactive cells co-labeled for PV (Fig 6B, E and Fig 7). 
This appeared to be inversely true as most PV-labeled cells were positive for mGluR5 (Fig 6D). 
There was also overlap seen between VIP and mGluR5 labeling, however, this was very rare 
(Fig 8B, D, E and Fig 9).  
There was a significant reduction in the number of mGluR5 cells that co-labeled for PV 
in layer V of the region 2.5 mm lateral to the microgyrus in PMG cortex (Fig 6B). However, 
there was no difference in the percentage of PV cells that were mGluR5 positive (Fig 6D). This 
suggests that either the observed change has nothing to do with regulation of mGluR5 or that 
both PV and mGluR5 are collectively down-regulated.  
There was an increase in the number of mGluR5-labeled cells that were negative for PV 
within the microgyrus of malformed cortex (Fig 6C). This was also true for mGluR5 positive 
cells that were negative for both PV and VIP (Fig 8C). These results indicate that the increase 
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could either be specific to either mGluR5-labeled SS cells, or pyramidal and other excitatory 
(non-GABAergic) neurons. However, the increase in mGluR5-positive-GAD67-negative cells 
within the microgyrus was around 20% of mGluR5 cells (roughly one cell per a frame), while 
the increase in mGluR5 positive, PV and VIP negative was only around 15% of mGluR5 cells 
(or roughly 0.5 cells per a frame, Fig 8F). This suggests that the increase is more likely due to 
non-GABAergic- mGluR5-labeled cells than SS or other GABAergic subtypes.   
 
Figure 5: Example of immunohistochemical staining of mGluR5 (A), PV (B), VIP (C) in layer 
III of the PMZ equivalent region in control cortex. D shows an overlap of all 3 stains. Scale bar = 
20 µm. 
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Figure 6: Cell counts and percentage of labeled cells for triple staining with mGluR5, PV, and 
VIP.  There was a selective decrease in PV-labeled cells within the deep layers of the region 2.5 
mm lateral to the lesion in PMG compared to control cortex (A). The decrease was also seen in 
PV cells that were mGluR5 positive (B). There was an increase in the number of mGluR5-
labeled cells that were not stained for PV, selectively within the microgyrus of PMG cortex (C). 
The percentage of PV-labeled cells that were mGluR5 positive was not significantly different 
between PMG and control cortex (D). The majority of mGluR5 cells co-labeled for PV in both 
PMG and control cortex (E). There was a trend toward an increase in the percent of mGluR5-
positive cells that were not stained for PV in PMG compared to control cortex (F, p=0.07).  *= t-
test, p<0.05. 
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Figure 7: Example of mGluR5 (A, D) and PV (B, E) immunohistochemical labeling for control 
(A-C) and PMG (D-F) cortex. Yellow arrows are examples of co-labeled cells and white arrows 
are examples of cells that solely labeled for mGluR5. These pictures were taken in layer III of 
the PMZ and equivalent region in control cortex. C and F show an overlap of the two stains. 
Scale bar = 20 µm. 
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Figure 8: Counts and percentages of cells labeled after mGluR5, PV, and VIP triple staining.  
There was a selective reduction in VIP-labeled cells within the microgyrus of PMG cortex (A). 
The mGluR5-labeled cells rarely were VIP positive in either control or PMG cortex (B). There 
was a selective increase in the number of mGluR5-labeled cells that were negative for both VIP 
and PV, within the microgyrus of PMG compared to control cortex (C).  This may once again 
reflect an increase in pyramidal or other excitatory neurons that stain for mGluR5 (see Fig 4G). 
There was no difference seen in the percentage of VIP cells that were positive for mGluR5 (D) 
or the percentage of mGluR5 cells that were positive for VIP (E). F shows that the percentage of 
mGluR5-labeled cells that did not label for PV or VIP was not different in control and PMG 
cortex. *= t-test, p<0.05. 
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Figure 9: Examples of overlap (C, F) in immunohistochemical labels for mGluR5 (A,D) and 
VIP (B,E). Yellow arrows are examples of co-labeled cells and white arrows are examples of 
cells that solely labeled for mGluR5. The co-labeled cell found in control cortex was in layer III 
2.5 mm lateral to the region equivalent to the microgyrus in malformed cortex (A-C). The co-
labeled cell found in malformed cortex was in layer III of the PMZ (D-F). Scale bar = 20 µm. 
 
3.3 Group I (mGluR1α  and mGluR5) Double Labeling in Control and PMG Cortex 
Double staining was performed with mGluR5 and mGluR1α markers to determine 
whether immunoreactive cells for each marker were seen as distinct cell populations (Fig 10). 
There was a significant decrease in the numbers of cells that stained for mGluR1α within the 
microgyrus of PMG cortex compared to the equivalent region of control cortex (Fig 11A, t-test, 
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p<0.05).  Labeling in control cortex revealed that there is overlap between group I markers. 
Around 5-16% of mGluR1α cells were mGluR5 positive while ~13-40% of mGluR5 cells were 
mGluR1α positive (Fig 11 C, D). There was no difference observed in the numbers of cells that 
were co-labeled for mGluR1α and mGluR5 in control compared to PMG cortex (Fig 11B-D).  
 
 
Figure 10: Example of immunohistochemical staining for mGluR5 (A,D) and mGluR1α (B, E) 
in the same sections of control (A-C) and PMG (D-F) cortex. C and F show overlap with the two 
stains. Yellow arrows are examples of co-labeled cells and white arrows are examples of cells 
that solely labeled for mGluR5. Scale bar = 20 µm. 
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Figure 11: Counts and percentages of cells after double staining for mGluR1α and mGluR5. 
There was a significant decrease in numbers of mGluR1α-stained cells selectively within the 
microgyrus of PMG compared to control cortex (A). There were cells that labeled for both 
mGluR1α and mGluR5; however, no changes were seen in the number of these cells (B). There 
were also no differences in the percent of mGluR5 positive cells that were mGluR1α positive (C) 
or the percent of mGluR1α-labeled cells that were mGluR5 positive (D). *= t-test, p<0.05. 
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3.4 mGluR1α ,  SS and VIP staining in Control and PMG Cortex 
Triple fluorescent staining was performed with mGluR1α and the interneuron 
subpopulation markers: SS and VIP (Fig 12). There were several findings from our control 
cortex that confirmed previous findings from other labs. Cells that were immunoreactive for 
mGluR1α overlapped with labeled VIP and SS cells (Figs 13-16). The majority of SS-stained 
cells were mGluR1α positive (Fig 13D). This was not inversely true as more than half of the 
mGluR1α-labeled cells were not immunoreactive for SS (Fig 13E). Labeling for mGluR1α was 
apparent at two intensities. The most intensely mGluR1α-labeled cells were negative for both 
VIP and SS, however the low-intensity mGluR1α cells often overlapped with these inhibitory 
interneuron markers (Figs 20, 14, 16). These observations were generally true for both control 
and PMG cortex. 
There was a trend toward an increase in the number of mGluR1α-labeled neurons that 
were also positive for SS selectively within the microgyrus (Fig 13B, t-test, p=0.06) compared to 
control cortex. This trend was mirrored by a trend toward an increase in the percentage of 
mGluR1α-labeled cells that were positive for SS (Fig 13E), as well as a significant decrease in 
the number of cells that were mGluR1α positive but SS negative (Fig 13C).  This likely reflects 
an increased expression of mGluR1α in SS neurons rather than an increase in the number of cells 
since there was no difference seen in the number of SS neurons within the microgyrus (13A).  
The significant decrease in the number of mGluR1α cells that were negative for: SS, VIP 
or SS and VIP selectively within the microgyrus in malformed cortex (Fig 15C) could represent 
a loss of expression in PV cells, pyramidal neurons or other cell types (note: 
NeuN/GAD/mGluR1α staining was not performed due to antibody limitations).  
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There was a significant increase in the number of mGluR1α positive cells that were 
negative for VIP in the deep cortical layers at the 2.5 mm location in malformed cortex (Fig 
15B). However, this increase was no longer apparent when considered relative to the percentage 
of mGluR1α immunoreactive cells (not shown, but graph is similar to Fig 15 F). Thus it may be 
more of a factor of an overall increase in mGluR1α-labeled cells at this location (although when 
numbers of mGluR1α cells were measured there was no significant difference, see Fig 11A). On 
the other hand that increase may be selective to cells negative for VIP.   
There was a trend towards a reduction in cells that labeled for mGluR1α and VIP in the 
superficial layers of the PMZ (Fig 15A). Since this trend was also apparent as a trend for 
percentage of VIP-labeled cells that stain for mGluR1α (Fig 15D), it may reflect a decrease in 
the expression of mGluR1α in these VIP cells. 
After all staining and counting for the results above were completed; observations were 
made that segregated mGluR1α-labeled cells by the differential level or intensity of staining 
among cells in both control and PMG cortex.  Some mGluR1α cells had a high level of stain (Fig 
18).  These cells tended to be nearly perfectly round, whereas the lower intensity mGluR1α cells 
had a more variable shape. The high intensity mGluR1α cells were typically negative for 
mGluR5 (Fig 19) as well as for VIP and SS labels (Fig 20).  The one staining combination that 
can easily be done but has not yet been performed is mGluR1α with Neun.  Thus we do not 
currently know if the high intensity mGluR1α cells are neurons. 
Taking into consideration these apparent distinct populations of mGluR1α-labeled cells, 
counts were made to determine whether there were differences in their expression in control and 
malformed cortex. There was a selective increase in the number of high intensity-labeled 
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mGluR1α cells in layer V of the PMZ (1 mm lateral to sulcus) in malformed compared to control 
cortex (Fig 17A). These results suggest that there is a selective increase in mGluR1α labeling 
within an unknown cell type. This same change was seen when calculated as the percent of 
mGluR1α cells that are high intensity (Fig 17B).  This calculation also showed a significant 
increase in the percent of mGluR1α cells that are high intensity at 1 mm lateral to the sulcus 
within layers II/III of PMG compared to control cortex. There was a significant reduction in the 
number of low intensity mGluR1α cells within layers II/III at the 1 mm lateral site of the PMG 
compared to control cortex (Fig 17C). There may be an increase in mGluR1α expression within 
the cell populations in the superficial layers and either novel mGluR1α expression in cells in 
layer V of PMG cortex or an increase in the number of cells that label for mGluR1α at high 
intensity. The high intensity-labeled mGluR1α cells showed no overlap with SS and rarely 
overlapped with VIP-labeled cells (3 total cells observed) and mGluR5 (2 total cells observed) 
(See figures 19 and 20 for typical high intensity mGluR1α cells that show no overlap with these 
markers).      
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Figure 12: Example of immunohistochemical staining for mGluR1α (A), SS (B) and VIP (C). D 
is an overlap of the three labels. These pictures were taken in layer III of the region equivalent to 
the PMZ in control cortex. Scale bar = 20 µm. 
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Figure 13: Counts and percentages of labeled neurons after staining for mGluR1α and SS in the 
same sections.  There was no statistical difference in numbers of SS-labeled cells between 
control and PMG cortex (A). There also was no difference between PMG and control cortex in 
the number of cells double labeled for mGluR1α and SS, although there was a trend towards an 
increase within the microgyrus, compared to control cortex (B, t-test, p=0.06). There was a 
significant decrease in number of mGluR1α positive cells that were negative for SS, selectively 
within the microgyrus compared to control cortex (C). There was no difference in the percentage 
of SS-labeled cells that were positive for mGluR1α (D). There was a trend towards an increase 
in the percent of mGluR1α cells that were also positive for SS within the microgyrus compared 
to control cortex (E, t-test, p=0.06).  That was mirrored by a trend toward a decrease in the 
percent of mGluR1α cells that were negative for SS, selectively within the microgyrus of PMG 
compared to control cortex (F, t-test, p=0.06). *= t-test, p<0.05. 
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Figure 14: Examples of mGluR1α (A,D), SS (B and E) double immunohistochemical labeling. 
C and F show overlap of the stains. In the overlap it is apparent that there are cells that are 
positive for each marker in control (C) and PMG (F) cortex.  Yellow arrows are examples of co-
labeled cells and white are examples of cells that solely labeled for mGluR1α. Pictures were 
taken within the microgyrus of malformed cortex and the equivalent region in control cortex. 
Scale bar = 20 µm. 
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Figure 15: Counts and percentages of labeled neurons after triple staining with mGluR1α, SS 
and VIP.  There was a trend towards a decrease in the number of cells double labeled for  
mGluR1α and VIP at one millimeter lateral to the sulcus in PMG compared to control cortex (A, 
t-test, p=0.06). For mGluR1α cells that were not immunopositive for VIP, there was a significant 
decrease in the microgyrus and a significant increase at 2.5 mm lateral to the sulcus within layer 
V of PMG compared to control cortex (B). There was also a significant decrease within the 
microgyrus for mGluR1α cells that were negative for SS and VIP (C).  There was no difference 
between PMG and control cortex in the percent of VIP stained cells that were also positive for 
mGluR1α (D).  There also was no significant difference in the percent of mGluR1α cells that 
were VIP positive (E), nor in the percent of mGluR1α cells that were both SS and VIP negative 
(F).  
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Figure 16: Example of mGluR1α (A, D) and VIP (B, E) double immunohistochemical staining 
in control and PMG cortex. C and F show there is overlap in labeling of the markers. Yellow 
arrows are examples of co-labeled cells and white arrows are examples of cells that solely 
labeled for mGluR1α. These pictures were taken within the microgyrus (Bottom) and equivalent 
region of control cortex (Top). 
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Figure 17: Counts and percentages for high and low intensity labeling of mGluR1α cells. There 
was a selective increase in the number of high intensity-labeled mGluR1α cells within the deep 
layers of the PMZ ( 1 mm lateral to sulcus) in malformed cortex (A). This increase can also be 
seen in the calculation of the percent of mGluR1α cells that are high intensity-labeled.  There is 
an increase at this location for superficial layers of the PMG compared to control cortex also.  
There is a selective decrease in the numbers of low intensity mGluR1α cells in superficial layers 
at the 1 mm site of PMG compared to control cortex (C). When calculated as percentage of 
mGluR1α cells that are low intensity, there is no significant difference between PMG and 
control cortex. *=t-test. P<0.05.  
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Figure 18: Examples of high intensity (yellow arrows) and low intensity (white arrows) 
mGluR1α-labeled cells in control (A) and PMG (B) cortex. These pictures were taken in layer III 
of the PMZ or equivalent region in control cortex. Scale bar = 20 µm.  
 
	  
	  
49	  
	  
 
Figure 19: Double immunohistochemical labeling for mGluR1α (A, D) and mGluR5 (B, E) in 
control (Top) and malformed cortex (Bottom). C and F show overlaps of these markers. High 
intensity mGluR1α-labeled cells (white arrows) rarely overlap with mGluR5 labeling. These 
pictures were taken in layer III of the PMZ (Top) and equivalent region in control cortex 
(Bottom). Scale bar = 20 µm. 
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Figure 20: Immunohistochemical labeling for mGluR1α (A, E), SS (B, F), and VIP (C, G) in 
control (Top) and malformed cortex (Bottom). D and H show overlap. High intensity mGluR1α-
labeled cells (white arrows) rarely overlap with SS and VIP positive cells. These pictures were 
taken in layer III of the PMZ (bottom) and equivalent region in control cortex (Top). Scale bar = 
20 µm. 
 
3.5 Results Summary: 
The majority of the differences seen in comparing malformed with control cortex 
appeared to be selective for the region within the microgyrus (Fig 21). There was additionally a 
selective decrease in the number of PV, and mGluR5/PV co- labeled cells in deep layers 2.5 mm 
lateral of the microgyrus. There was also an increase in mGluR1α and mGluR1α positive/VIP 
negative labeled cells within this region. Lastly, there was an increase in the number/percentage 
of high intensity labeled mGluR1α cells in layer V of the PMZ, and an increase in the percentage 
of high intensity cells in the superficial layers of the PMZ that coincided with a reduction in low 
intensity mGluR1α cells.  
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Figure 21: Overall summary of all cell counts performed. Cells marked I are significant 
increases. Those marked D is significant decreases. TI and TD are trend increase and trend 
decrease respectively. Cells marked ND were those in which no difference was seen and – 
indicates too few cells were counted to test. 
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3.6 Additional Statistical Tests: 
 A two-way ANOVA (group versus location) with repeated measure (3 slides from which 
measurements were taken) was performed as an additional statistical measure.  The groups were 
control and PMG.  The five locations were MG (the microgyrus), layers III and V at 1.0 mm 
lateral to the MG, layers III and V at 2.5 mm later to the MG.  This analysis showed a significant 
interaction between group and location for the high intensity mGluR1a labeled cells.  Pairwise 
contrasts showed that for this marker, layer V of the PMZ region of PMG cortex was 
significantly increased compared to the homologous region of control cortex.  There were no 
other significant differences in group or the interaction between group and location.  A number 
of stains showed significance in location, which in most cases was due to a difference between 
layer III and layer V.  Since some group and interactions were near significance (ex. p=0.07), 
likely additional animals should be included in this study. 
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4.1 Discussion 
 The aim of the present study was to determine whether there were alterations in group I 
mGluR expression in interneuron populations in freeze lesion induced malformed cortex. 
Immunohistochemical labels used were: NeuN, GAD67, PV, SS, VIP, mGluR1α and mGluR5. 
The following observations were made in both control and malformed cortex: (1) mGluR5 
labeling is seen almost entirely in neurons; (2) the majority of mGluR5 positive cells were GAD-
labeled interneurons; (3) The majority of mGluR5 and mGluR1α labeling does not overlap; (4) 
mGluR1α labeling occurs at two intensities (high and low), with the high intensity-labeled cells 
not staining for mGluR5, SS or VIP.  
 Several previous studies have reported alterations in specific interneuron populations in 
malformed cortex (Jacobs et al., 1996; Rosen et al., 1998; Schwarz et al., 2000). Our findings 
corroborate a decrease in PV staining in the deep layers lateral to the microgyrus, which has been 
shown to persist in older animals (Rosen et al., 1998). This finding is significant considering 
withdrawal of inhibition is thought to be a mechanism for epilepsy (Dichter and Ayala, 1987). 
However it is not currently known definitively whether or not the loss of PV-labeled cells 
actually reflects a loss of inhibitory neurons.  In fact, our findings support the idea that there is 
not a loss in the total number of GAD-labeled cells in malformed cortex (Schwarz et al., 2000). 
We did, however, see a selective reduction in VIP-labeled cells within the microgyrus of PMG 
cortex. This has not been previously reported in the freeze lesion model. Interestingly, there was 
not a reduction in the number of GAD-labeled cells in this region, nor was there an increase seen 
in the number of SS or PV-labeled cells. This implies that either a portion of GAD-labeled cells 
lost their immunoreactivity to the VIP antibody, or there may be slight indistinguishable 
increases in the number of SS- and PV-labeled cells to compensate for the reduction.  
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There were no dramatic changes observed in numbers of group I mGluR-labeled cells 
that were co-labeled with the specific interneuron markers used here, except selectively within 
the microgyrus. These alterations may contribute to the hyperexcitable state of the cortex, 
although the epileptiform activity is thought to originate from the adjacent PMZ rather than the 
microgyrus itself. There was a selective decrease in the number of mGluR1α-labeled cells within 
the microgyrus of malformed cortex. This reduction could be explained by previous findings that 
mGluR1α plays a role in neonatal hypoxia/ischemia excitotoxicity (Xu et al., 2007; Zhou et al., 
2009). This excitotoxicity was seen to occur by means of glutamate release in cortical cultured 
neurons (Xu et al., 2007). This release acts on NMDA receptors which cause calpain-mediated 
truncation of the C terminal domain of mGluR1α receptors(Xu et al., 2007). This truncation does 
not result in a loss of function in the receptor; instead alters the intracellular signaling (Xu et al., 
2007). This ultimately leads to a reduction in the phosphorylation of downstream proteins (Akt) 
and, ultimately, in increased cell death (Xu et al., 2007). The inhibition of this truncation by 
means of a fusion peptide was shown to have neuroprotective effects (Xu et al., 2007). The 
truncation of mGluR1α also results in a translocation of the receptors from the dendrites to axons 
(Xu et al., 2007). No change was observed in the levels of mGluR5 indicating it is not truncated 
in a similar fashion (Xu et al., 2007).  
Interestingly Group I mGluRs have also been shown to have neuroprotective properties 
(Baskys et al., 2005). Long term treatment with DHPG, prior to administered NMDA, reduced 
excitotoxic injury in hippocampus cultured neurons (Baskys et al., 2005). The therapeutic 
implications of these studies for patients with PMG are limited considering the application of 
mGluR1α antagonists to prevent hypoxia/ischemia excitotoxicity would have to be administered 
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not only during pregnancy but prior to diagnosis and even prior to the event that creates the 
malformation. This does not seem feasible.  
The neuroprotective properties of group I mGluRs may, however, explain the selective 
reductions seen in specific cell populations. There was a reduction seen in mGluR1α-labeled 
cells within the microgyrus; however, there was no reduction in cells that co-labeled for 
mGluR1α and mGluR5. These cells may have remained active prior to and during the hypoxic 
event and thus were protected. There was also a trend seen towards a selective increase in 
mGluR1α-labeled cells that were SS positive within the microgyrus of PMG cortex. This trend 
was mirrored by an increase in the percentage of mGluR1α-labeled cells that were positive for 
SS. If true, this likely represents an increase in the expression of mGluR1α in SS neurons rather 
than an increase in the number of cells since there was no increase observed in SS-labeled cells 
within the microgyrus. There was also a selective decrease within the microgyrus in the number 
of mGluR1α-labeled cells that were either negative for SS or VIP, or were negative for both 
markers. This may reflect a loss, or reduction, of mGluR1α expression within PV, pyramidal 
neurons or glial cells.  
There was a decrease seen in the percentage of mGluR5-labeled cells that were GAD-
positive selectively within the microgyrus in PMG cortex. There was no difference seen in the 
number of mGluR5, and GAD-labeled cells in control and lesioned animals. This suggests that 
there is an increased expression of mGluR5 in pyramidal or other non-GABAergic neurons 
within this region. Additionally, in sections triple-stained for mGluR5, VIP and PV showed a 
selective increase, within the microgyrus, of mGluR5-labeled cells that were negative for PV or 
negative for both PV and VIP. This could reflect increased expression in SS interneurons or in 
pyramidal and other non-GABAergic neurons. There was a reduction in the number of mGluR5-
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labeled PV positive cells in the microgyrus, however this reduction lost significance when 
viewed as the percentage of PV cells that were mGluR5 positive. This suggests that the change 
observed may have nothing to do with the regulation of mGluR5 or both PV and mGluR5 may 
be down-regulated together. 
These selective alterations within the microgyrus may have significant effects in neuronal 
networks; however, it has previously been shown that resection of the microgyrus has no effect 
on the generation of epileptic activity in the PMZ (Jacobs et al., 1999a). Also, similarly, it has 
been shown that stimulation within the microgyrus does not generate the late multiphasic 
epileptiform activity seen in the PMZ (Jacobs et al., 1999a).  
There was an increase in the number of mGluR1α-labeled cells that were negative for 
VIP at the distance 2.5 mm lateral to the microgyrus within the deep layers, relative to the 
homologous region of control cortex. This increase was not apparent when considered relative to 
the percent of all mGluR1α-labeled cells. Thus the increase may be due to an overall increase in 
mGluR1α staining or the increase may be selective to VIP negative cells. There was a trend 
towards a selective decrease in mGluR1α-labeled cells that were positive for VIP in the 
superficial layers of the PMZ. This was also seen in the percentage of VIP cells that were 
mGluR1α-positive and thus may reflect a decrease in the expression of mGluR1α in VIP cells. 
These alterations in regions distant to the microgyrus reflect the vast extent of the abnormalities 
associated with this malformation.  
 Previous physiological findings suggest a novel mechanism for the activation of LTS 
cells via mGluR5 within the PMZ of malformed cortex. In conducting this experiment it was 
hypothesized that a difference would be apparent in mGluR5 labeling within interneurons in the 
	  
	  
58	  
	  
PMZ. This difference was not observed, as there was no large increase seen in cellular 
expression that could account for the significant change in the mGluR5 physiology. However, 
this does not rule out altered expression of the receptor within interneuron subtypes. One 
possible explanation is an increase in receptor expression at the membrane level in mGluR5-
labeled cells. One method that could be used in future studies for determining whether this was 
occurring would be through electron microscopic receptor localization (Lujan, 2004). This 
method can be used to determine the location and density of G protein coupled receptors (Lujan, 
2004). Specifically the postembedding immunogold technique is used to localize synaptic 
receptors (Lujan, 2004). Another potential explanation for the mGluR5 physiology is an increase 
in the efficacy of the individual postsynaptic receptors. One method to analyze the levels of 
response would be to use calcium imaging to measure the intensity of calcium signaling in cells 
(Gobel and Helmchen, 2007).  
As previously mentioned, mGluR1α-labeling occurred at two intensities. When analyzed 
separately, high intensity mGluR1α cells show nearly zero overlap with VIP, SS and mGluR5 
labeling. There is a selective increase in the number and percentage of high intensity mGluR1α-
labeled cells in layer V and in the percentage of high intensity cells in layer III of the PMZ. 
 The increase in high intensity mGluR1α-labeled cells may account for the increased 
physiological response in the deep layers of the PMZ to group I mGluR agonists. It does not, 
however, address the dramatic change in the mGluR5 physiology. Follow-up studies are 
necessary to determine the subtype of these high intensity mGluR1 α-labeled cells: interneuron, 
pyramidal or glial. These cells are seen in both control and malformed cortex. Previous findings 
suggest that mGluR1α labeling is isolated almost entirely to GABAergic neurons (Stinehelfer et 
al., 2000). This would suggest that these high intensity cells are interneurons. A way in which 
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this could be tested would be double labeling sections with NeuN, GAD67 or another 
interneuron marker. GAD67 may not be the best GABAergic cell marker, since it does not label 
every GABAergic cell (Roper et al., 1999). Our findings support these results as only around 
eight percent of neurons were GAD67 positive in the cortical regions examined. This is a 
markedly lower percentage than the 20-30% of cortical neurons proposed by Markram et al. The 
makers PV, SS and VIP are thought to label around 82% of cortical interneurons (Rudy et al., 
2011). The mGluR1α high intensity cells appear to be negative for SS and VIP labeling. They 
also appear to be non-overlapping with mGluR5-labeled cells, which are mostly PV positive. 
This suggests that high intensity mGluR1α cells may belong to the 18% of interneurons that do 
not express these markers. The majority (~80%) of this population of interneurons express reelin 
(Rudy et al., 2011).  
 Neurogliaform (NGF) cells are amongst this class of reelin expressing interneurons 
(Rudy et al., 2011). NGF cells are small ovoid multipolar cells with a 100-200 micron wide 
dendritic field and an axonal arbor that is twice that size (Druga, 2009; Kawaguchi and Kubota, 
1997; Olah et al., 2007). These cells synapse on pyramidal cells as well as various interneurons 
(Olah et al., 2007). They have been shown to be electrically coupled amongst themselves (NGF 
to NGF) as well as with other interneuron cell types (Olah et al., 2007). These observations have 
been made in both rat and human cortex (Olah et al., 2007). NGF cells have the ability to release 
sufficient GABA for volume transmission within their axonal field; and are thus capable of 
synchronizing synaptic activity across distances around 200 microns (Olah et al., 2009). An 
increase in NGF cells within the PMZ could account for increased or novel avenues for 
synchronized cortical activity in the malformed brain. 
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 NGF cells have been shown to be reliant on cortical activity prior to P3 for proper 
cortical migration (De Marco Garcia et al., 2011). Reduced activity was shown to result in NGF 
cells failing to migrate to the proper location in superficial layers. They were shown to settle in 
deeper layers than NGF cells found in control cortex (De Marco Garcia et al., 2011). There was 
also a reduction in the length of the axonal arborizations of these NGF cells as well as in the 
complexity (not length) of their dendritic trees (De Marco Garcia et al., 2011). This may account 
for the increase in mGluR1α cells found in the deep layers of the PMZ. However, it would 
suggest a decrease in the high intensity mGluR1α-labeled cells in the superficial layers of the 
same region. This was not observed in our counts. There was, however, an increase seen in the 
percentage of high intensity mGluR1α-labeled cells in superficial layers of the PMZ. This may 
indicate a compensatory mechanism. There may be a reduction in high intensity mGluR1α-
labeled NGF cells in this region due to improper migration that could initiate a compensatory 
increase in mGluR1α expression within another cell type that ordinarily labels at a lower 
intensity.   
Overall, these studies suggest that the increased physiological response to mGluRI agonists may 
in part be due to neurogliaform interneurons that label at a high intensity for mGluR1α. The 
increase in number of these cells occurs in the PMZ, where the increased physiological responses 
were observed.  The results of this study however cannot account for the increased response to 
mGluR5 receptors, specifically.  Since no change in numbers of mGluR5 cells was observed in 
the PMZ, these results suggest that instead, an increased number of receptors or intracellular 
signaling response must account for the physiological findings.  Further, in the PMZ, there is no 
increased expression of mGluR5 in cell types different from those in control cortex.  Since the 
majority of mGluR5 labeling was found in the PV interneuron subtype, this subtype may 
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participate in the increased responsiveness of PMZ cortex to mGluRI agonists.  It is also possible 
that SS cells participate, since ~20% of mGluR5 labeled cells did not stain for either PV or VIP, 
leaving SS as the other major interneuron subtype.  Further experiments are necessary to verify 
physiologically which subtype is responding to the mGluR5 activation as well as to determine 
the cellular type of the high intensity mGluR1α-labeled cells. 
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